Physician profile
John O'Connor
NPI 1649249806
$8,301.01
in general payments reported to CMS, 2019-2025
35 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $536 · 2021: $965 · 2022: $1,370 · 2023: $1,504 · 2024: $1,623 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,190.03 | 2019-2025 | |
| Janssen Biotech, INC. | $1,261.72 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,066.84 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $527.51 | 2021-2024 | Zeposia |
| Pfizer INC. | $476.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $442.52 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $391.50 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $242.53 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $205.93 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $176.87 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $133.71 | 2024 | Voquezna |
| Genzyme Corporation | $109.11 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $109.07 | 2019-2023 | Zinplava, Dificid |
| Daiichi Sankyo INC. | $105.88 | 2019-2023 | Injectafer |
| Fujifilm Healthcare Americas Corporation | $101.24 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $98.73 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $82.35 | 2021-2022 | |
| Braintree Laboratories, INC. | $75.42 | 2019-2021 | |
| Madrigal Pharmaceuticals | $66.86 | 2025 | Rezdiffra |
| Ucb, INC. | $46.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.57 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $41.08 | 2022-2023 | |
| Boston Scientific Corporation | $36.10 | 2020-2023 | Endoarmor |
| Allergan, INC. | $30.70 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $29.66 | 2019 | |
| Intercept Pharmaceuticals, INC. | $29.64 | 2019-2020 | |
| Redhill Biopharma INC. | $28.43 | 2020 | |
| Organon LLC | $26.70 | 2024 | |
| Celltrion USA INC. | $26.12 | 2024 | Zymfentra |
| Novo Nordisk INC | $22.13 | 2025 | Wegovy |
| Alfasigma USA, INC. | $17.47 | 2020 | |
| Aimmune Therapeutics, INC. | $15.33 | 2025 | Zenpep |
| Shire North American Group INC | $15.32 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.41 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John O'Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.